| Identification | Back Directory | [Name]
SL0101 | [CAS]
77307-50-7 | [Synonyms]
SL0101
SL 0101-1
3'',4''-Di-O-acetylafzelin
Kaempferol 3-O-(3'',4''-di-O-acetyl-alpha-L-rhamnopyranoside)
3-(3-O,4-O-Diacetyl-α-L-rhamnopyranosyloxy)-4',5,7-trihydroxyflavone
3-[(3-O,4-O-Diacetyl-6-deoxy-α-L-mannopyranosyl)oxy]4',5,7-trihydroxyflavone
2-(4-Hydroxyphenyl)-4-oxo-5,7-dihydroxy-4H-1-benzopyran-3-yl 3-O,4-O-diacetyl-α-L-rhamnopyranoside
2-(4-Hydroxyphenyl)-3-(3-O,4-O-diacetyl-α-L-rhamnopyranosyloxy)-5,7-dihydroxy-4H-1-benzopyran-4-one
3-[(3,4-Di-O-acetyl-6-deoxy-α-L-mannopyranosyl)oxy]-5,7-dihydro-2-(4-hydroxyphenyl)-4H-1benzopyran-4-one
3-[(3,4-Di-O-acetyl-6-deoxy-α-L-Mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one | [Molecular Formula]
C25H24O12 | [MDL Number]
MFCD09842349 | [MOL File]
77307-50-7.mol | [Molecular Weight]
516.453 |
| Chemical Properties | Back Directory | [Appearance]
Tan Solid | [Melting point ]
128-132°C | [Boiling point ]
753.0±60.0 °C(Predicted) | [density ]
1.57±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Acetone (Slightly), Methanol (Slightly) | [form ]
Yellow solid | [pka]
6.20±0.40(Predicted) | [color ]
Pale Yellow to Brown | [InChIKey]
SXOZSDJHGMAEGZ-IGKKHSBFSA-N | [SMILES]
O1[C@H]([C@@H]([C@@H]([C@H]([C@@H]1C)OC(=O)C)OC(=O)C)O)Oc2[c](c3c([o]c2c4ccc(cc4)O)cc(cc3O)O)=O |
| Hazard Information | Back Directory | [Chemical Properties]
Tan Solid | [Uses]
A potent and selective inhibitor of p90 Rsk, without inhibiting the function of upstream kinases such as MEK, Raf, or PKC | [Biological Activity]
Selective inhibitor of p90 ribosomal S6 kinase (RSK) (IC 50 = 89 nM for RSK2). Does not inhibit upstream kinases such as MEK, Raf and PKC.? Inhibits the growth of MCF-7 human breast cancer cells with no effect on the normal breast cell line. | [Description]
The p90 ribosomal S6 kinases (RSK) 1-4 are downstream members of the extracellular signal-regulated kinase (ERK)/MAPK cascade. SL 0101-1 is a kaempferol glycoside, isolated from the tropical plant F. refracta, that selectively inhibits RSK2 with an IC50 value of 89 nM (Ki = 1 μM) without interfering with upstream activators of RSK, including ERK, MEK, EGFR, and PKC. At 100 μM, SL 0101-1 inhibits the proliferation of MCF-7 breast cancer cells, arresting cells in the G1 phase of the cell cycle. SL 0101-1 has been used to characterize the intracellular signaling events associated with angiotensin II-induced tyrosine kinase activation with a concentration of 30 μM attenuating angiotensin II-induced cell proliferation. | [storage]
-20°C | [References]
[1] JEFFREY A. SMITH. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.[J]. Cancer research, 2005, 146 1: 1027-1034. DOI: 10.1158/0008-5472.1027.65.3
[2] MICHAEL D GODENY Peter P S. ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1.[J]. American journal of physiology. Cell physiology, 2006, 291 6: C1308-17. DOI: 10.1152/ajpcell.00618.2005 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|